Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23137982 | 0.84 | KMT2A (0.41) | — | |
| SCHEMBL10210690 | 0.82 | KDM4E (0.39) | KDM4EKDM5A | |
| SCHEMBL19736266 | 0.82 | EPHX1 (0.41) | KDM4E | |
| SCHEMBL24963547 | 0.81 | EPHX1 (0.43) | KDM4E | |
| SCHEMBL24904230 | 0.74 | KDM4E (0.36) | KDM4E | |
| SCHEMBL23137863 | 0.73 | EPHX1 (0.39) | KDM4E | |
| SCHEMBL24316202 | 0.73 | KAT2B (0.36) | KAT2BKDM4EKDM5A | |
| SCHEMBL18347953 | 0.73 | KDM5A (0.45) | KDM4EKDM5A | |
| SCHEMBL16078081 | 0.73 | KDM5A (0.45) | KDM4EKDM5A | |
| SCHEMBL13192995 | 0.73 | KDM5A (0.45) | KDM4EKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | KAT2B 2198/4885KAT2A 910/4885KDM4E 2704/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | KAT2B 2198/4885KAT2A 910/4885KDM4E 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.